Exelixis, Inc. (EXEL) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Alameda, CA, アメリカ. 現CEOは Michael Morrissey.
EXEL を有する IPO日 2000-04-17, 1,147 名の正社員, に上場 NASDAQ Global Select, 時価総額 $12.3B.
Exelixis, Inc. is an oncology-focused biotechnology company engaged in the discovery, development, and commercialization of cancer treatments. The company's marketed products include CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan. Exelixis maintains an active pipeline of investigational therapies, including XL092, XB002, and XL102, which target various cancer mechanisms through tyrosine kinase inhibition and other novel pathways. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its research and development efforts. Headquartered in Alameda, California, Exelixis was founded in 1994 and operates globally in the oncology market.
